Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS‐like tyrosine kinase 3‐internal tandem duplication with central nervous system involvement
oleh: Makiko Suga, Kentaro Fukushima, Tomoaki Ueda, Yasuyuki Arai, Shunsaku Nakagawa, Yosuke Minami, Jun Toda, Akihisa Hino, Jiro Fujita, Takafumi Yokota, Naoki Hosen
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2022-02-01 |
Deskripsi
Abstract FMS‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD) mutation‐positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for FLT3‐ITD‐positive AML‐primary induction failure patients with central nervous system involvement.